We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pulsed Dose Rate Brachytherapy of Lip Carcinoma: Clinical Outcome and Quality of Life Analysis.
- Authors
El Ayachy, Radouane; Sun, Roger; Ka, Kanta; Laville, Adrien; Duhamel, Anne-Sophie; Tailleur, Anne; Dumas, Isabelle; Bockel, Sophie; Espenel, Sophie; Blanchard, Pierre; Tao, Yungan; Temam, Stéphane; Moya-Plana, Antoine; Haie-Meder, Christine; Chargari, Cyrus; Rieken, Stefan
- Abstract
Simple Summary: Lip cancer accounts for 25–30% of all oral cancers, with 23,000 new cases per year in the world. Carcinomas of the lip can be successfully treated with different methods: surgery, external beam radiotherapy (EBRT) and brachytherapy. The choice of the treatment depends on the tumor size, location and expected functional and esthetic results with each option, but also depends on treatment type accessibility. There are no randomized studies comparing these different treatment strategies. In this article, we investigated the complications and outcomes of patients treated with interstitial pulsed dose rate brachytherapy in our institution. Purpose: Lip carcinoma represents one of the most common types of head and neck cancer. Brachytherapy is a highly effective therapeutic option for all stages of lip cancers. We report our experience of pulsed dose rate brachytherapy (PDR) as treatment of lip carcinoma. Methods and Materials: this retrospective single center study included all consecutive patients treated for a lip PDR brachytherapy in our institution from 2010 to 2019. The toxicities and outcomes of the patients were reported, and a retrospective quality of life assessment was conducted by phone interviews (FACT H&N). Results: From October 2010 to December 2019, 38 patients were treated in our institution for a lip carcinoma by PDR brachytherapy. The median age was 73, and the majority of patients presented T1-T2 tumors (79%). The median total dose was 70.14 Gy (range: 60–85 Gy). With a mean follow-up of 35.4 months, two patients (5.6%) presented local failure, and seven patients (19%) had lymph node progression. The Kaplan–Meier estimated probability of local failure was 7.2% (95% CI: 0.84–1) at two and four years. All patients encountered radiomucitis grade II or higher. The rate of late toxicities was low: three patients (8.3%) had grade II fibrosis, and one patient had grade II chronic pain. All patients would highly recommend the treatment. The median FACT H&N total score was 127 out of 148, and the median FACT H&N Trial Outcome Index was 84. Conclusions: This study confirms that an excellent local control rate is achieved with PDR brachytherapy as treatment of lip carcinoma, with very limited late side effects and satisfactory functional outcomes. A multimodal approach should help to improve regional control.
- Subjects
CANCER treatment; CHRONIC pain; CONFIDENCE intervals; TIME; LIP tumors; RETROSPECTIVE studies; INTERVIEWING; LYMPH nodes; FIBROSIS; HEALTH outcome assessment; TREATMENT effectiveness; QUALITY of life; RADIATION doses; KAPLAN-Meier estimator; DESCRIPTIVE statistics; RADIOISOTOPE brachytherapy; PROBABILITY theory; EVALUATION
- Publication
Cancers, 2021, Vol 13, Issue 6, p1387
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers13061387